Search our extensive Laboratory Test Directory to find test codes, ordering recommendations, specimen stability information, Test Fact Sheets, and more.
Recommendations when to order or not order the test. May include related or preferred tests.
Screen for 11-beta hydroxylase deficiency.
New York DOH Approval Status
Indicates whether a test has been approved by the New York State Department of Health.
This test is New York state approved.
Specimen Required
Patient PreparationInstructions patient must follow before/during specimen collection.
Collect between 6-10 a.m.
CollectSpecimen type to collect. May include collection media, tubes, kits, etc.
Serum separator tube or green (sodium or lithium heparin). Also acceptable: Pink (K2EDTA).
Specimen PreparationInstructions for specimen prep before/after collection and prior to transport.
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1.2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.7 mL)
Storage/Transport TemperaturePreferred temperatures for storage prior to and during shipping to ARUP. See Stability for additional info.
Refrigerated.
Unacceptable ConditionsCommon conditions under which a specimen will be rejected.
RemarksAdditional specimen collection, transport, or test submission information.
StabilityAcceptable times/temperatures for specimens. Times include storage and transport time to ARUP.
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
Performed
Days of the week the test is performed.
Sun-Sat
Reported
Expected turnaround time for a result, beginning when ARUP has received the specimen.
1-8 days
Reference Interval
Normal range/expected value(s) for a specific disease state. May also include abnormal ranges.
Test Number
Components
Reference Interval
Testosterone by Mass Spec
Age
Male (ng/dL)
Female (ng/dL)
Premature (26-28 weeks)
59-125
5-16
Premature (31-35 weeks)
37-198
5-22
Newborn
75-400
20-64
1-5 months
14-363
Less than 20
6-24 months
Less than 37
Less than 9
2-3 years
Less than 15
Less than 20
4-5 years
Less than 19
Less than 30
6-7 years
Less than 13
Less than 7
8-9 years
2-8
1-11
10-11 years
2-165
3-32
12-13 years
3-619
6-50
14-15 years
31-733
6-52
16-17 years
158-826
9-58
18-39 years
300-1080
9-55
40-59 years
300-890
9-55
60 years and older
300-720
5-32
Premenopausal (18 years and older)
Not Applicable
9-55
Postmenopausal
Not Applicable
5-32
Tanner Stage I
2-15
2-17
Tanner Stage II
3-303
5-40
Tanner Stage III
10-851
10-63
Tanner Stage IV-V
162-847
11-62
11-Deoxycortisol, HPLC-MS/MS
Age
Male (ng/dL)
Female (ng/dL)
Premature (26-28 weeks)
110-1376
110-1376
Premature (29-36 weeks)
70-455
70-455
Full Term (1-5 months)
10-200
10-200
6-11 months
10-276
10-276
1-3 years
7-202
7-247
4-6 years
8-235
8-291
7-9 years
Less than or equal to 120
Less than or equal to 94
10-12 years
Less than or equal to 92
Less than or equal to 123
13-15 years
Less than or equal to 95
Less than or equal to 107
16-17 years
Less than or equal to 106
Less than or equal to 47
18 years and older
Less than 50
Less than 33
Tanner Stage I
Less than or equal to 105
Less than or equal to 94
Tanner Stage II
Less than or equal to 108
Less than or equal to 136
Tanner Stage III
Less than or equal to 111
Less than or equal to 99
Tanner Stage IV & V
Less than or equal to 83
Less than or equal to 50
After metyrapone stimulation
Greater than 8000
Greater than 8000
17-Hydroxyprogesterone, HPLC-MS/MS
Age
Male (ng/dL)
Female (ng/dL)
Premature (26-28 weeks)
124-841
124-841
Premature (29-35 weeks)
26-568
26-568
Full term Day 3
7-77
7-77
4 days-30 days
Less than 200
7-106
1 month-2 months
Less than 200
13-106
3 months-5 months
3-90
13-106
6 months-1 year
Less than or equal to 148
Less than or equal to 148
2-3 years
Less than or equal to 228
Less than or equal to 256
4-6 years
Less than or equal to 208
Less than or equal to 299
7-9 years
Less than or equal to 63
Less than or equal to 71
10-12 years
Less than or equal to 79
Less than or equal to 129
13-15 years
9-140
9-208
16-17 years
24-192
Less than or equal to 178
18 years and older
Less than 139
Less than 207
Follicular
Not Applicable
15-70
Luteal
Not Applicable
35-290
Tanner Stage I
Less than or equal to 62
Less than or equal to 74
Tanner Stage II
Less than or equal to 104
Less than or equal to 164
Tanner Stage III
Less than or equal to 151
13-209
Tanner Stage IV-V
20-173
7-170
Androstenedione by TMS
Age
Male (ng/mL)
Female (ng/mL)
Premature Infants (26-28 weeks Day 4)
0.92-2.82
0.92-2.82
Premature Infants (31-35 weeks Day 4)
0.80-4.46
0.80-4.46
Full Term Infants (1-7 days)
0.20-2.90
0.20-2.90
8-30 days
0.18-0.80
0.18-0.80
1-5 months
0.06-0.68
0.06-0.68
6-24 months
0.03-0.15
Less than 0.15
2-3 years
Less than 0.11
Less than 0.16
4-5 years
0.02-0.17
0.02-0.21
6-7 years
0.01-0.29
0.02-0.28
8-9 years
0.03-0.30
0.04-0.42
10-11 years
0.07-0.39
0.09-1.23
12-13 years
0.10-0.64
0.24-1.73
14-15 years
0.18-0.94
0.39-2.00
16-17 years
0.30-1.13
0.35-2.12
18-39 years
0.33-1.34
0.26-2.14
40 years and older
0.23-0.89
0.13-0.82
Premenopausal
Not Applicable
0.26-2.14
Postmenopausal
Not Applicable
0.13-0.82
Tanner Stage I
0.04-0.32
0.05-0.51
Tanner Stage II
0.08-0.48
0.15-1.37
Tanner Stage III
0.14-0.87
0.37-2.24
Tanner Stage IV-V
0.27-1.07
0.35-2.05
Dehydroepiandrosterone by TMS
Age
Male (ng/mL)
Female (ng/mL)
Premature
Less than 40
Less than 40
0-1 days
Less than 11
Less than 11
2-6 days
Less than 8.7
Less than 8.7
7 days-1 month
Less than 5.8
Less than 5.8
1-5 months
Less than 2.9
Less than 2.9
6-24 months
Less than 2.5
Less than 1.99
2-3 years
Less than 0.63
Less than 0.85
4-5 years
Less than 0.95
Less than 1.03
6-7 years
0.06-1.93
Less than 1.79
8-9 years
0.10-2.08
0.14-2.35
10-11 years
0.32-3.08
0.43-3.78
12-13 years
0.57-4.10
0.89-6.21
14-15 years
0.93-6.04
1.22-7.01
16-17 years
1.17-6.52
1.42-9.00
18-39 years
1.33-7.78
1.33-7.78
40 years and older
0.63-4.70
0.63-4.70
Postmenopausal
Not Applicable
0.60-5.73
Tanner Stage I
0.11-2.37
0.14-2.76
Tanner Stage II
0.37-3.66
0.83-4.87
Tanner Stage III
0.75-5.24
1.08-7.56
Tanner Stage IV-V
1.22-6.73
1.24-7.88
Interpretive Data
May include disease information, patient result explanation, recommendations, or details of testing.
Free or bioavailable testosterone measurements may provide supportive information.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
The American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Connect Sign In
